News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
129,910 Results
Type
Article (4300)
Company Profile (88)
Press Release (125522)
Multimedia
Podcasts (3)
Webinars (6)
Section
Business (42058)
Career Advice (208)
Deals (6154)
Drug Delivery (13)
Drug Development (17410)
Employer Resources (18)
FDA (1486)
Job Trends (2780)
News (66171)
Policy (3647)
Tag
2024 BioCapital Digital (2)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Digital (7)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (6)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (4)
2025 Lone Star Bio Digital (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (1)
Academia (292)
Adcomms (1)
Allergies (16)
Alliances (11461)
ALS (28)
Alzheimer's disease (330)
Antibody-drug conjugate (ADC) (30)
Approvals (1501)
Artificial intelligence (50)
Autoimmune disease (12)
Automation (4)
Bankruptcy (38)
Best Places to Work (2248)
BIOSECURE Act (14)
Biosimilars (8)
Biotechnology (85)
Bladder cancer (23)
Brain cancer (6)
Breast cancer (73)
Cancer (582)
Cardiovascular disease (17)
Career advice (197)
Career pathing (5)
CAR-T (62)
Cell therapy (175)
Cervical cancer (6)
Clinical research (14152)
Collaboration (264)
Compensation (116)
Complete response letters (2)
COVID-19 (428)
CRISPR (10)
C-suite (106)
Cystic fibrosis (27)
Data (606)
Depression (8)
Diabetes (51)
Diagnostics (698)
Digital health (1)
Diversity, equity & inclusion (8)
Drug discovery (43)
Drug pricing (5)
Drug shortages (2)
Duchenne muscular dystrophy (20)
Earnings (12539)
Editorial (4)
Employer resources (18)
Events (24772)
Executive appointments (275)
FDA (1729)
Featured Employer (13)
Frontotemporal dementia (5)
Funding (226)
Gene editing (25)
Generative AI (4)
Gene therapy (84)
GLP-1 (111)
Government (345)
Guidances (10)
Healthcare (1525)
Huntington's disease (6)
IgA nephropathy (8)
Immunology and inflammation (23)
Indications (11)
Infectious disease (457)
Inflammatory bowel disease (52)
Inflation Reduction Act (1)
Influenza (17)
Intellectual property (36)
Interviews (17)
IPO (2932)
IRA (4)
Job creations (667)
Job search strategy (184)
Kidney cancer (2)
Labor market (9)
Layoffs (38)
Legal (638)
Liver cancer (13)
Lung cancer (44)
Lymphoma (59)
Management (4)
Manufacturing (90)
MASH (10)
Medical device (397)
Medtech (397)
Mergers & acquisitions (3418)
Metabolic disorders (119)
Multiple sclerosis (25)
NASH (1)
Neurodegenerative disease (17)
Neuropsychiatric disorders (3)
Neuroscience (457)
NextGen: Class of 2025 (857)
Non-profit (273)
Northern California (839)
Now hiring (6)
Obesity (60)
Opinion (37)
Ovarian cancer (29)
Pain (21)
Pancreatic cancer (24)
Parkinson's disease (40)
Partnered (4)
Patents (57)
Patient recruitment (29)
Peanut (12)
People (16473)
Pharmaceutical (8)
Phase I (5608)
Phase II (6766)
Phase III (3462)
Pipeline (322)
Policy (26)
Postmarket research (209)
Preclinical (2428)
Press Release (51)
Prostate cancer (21)
Psychedelics (2)
Radiopharmaceuticals (46)
Rare diseases (69)
Real estate (1445)
Recruiting (10)
Regulatory (2970)
Reports (13)
Research institute (298)
Resumes & cover letters (20)
Rett syndrome (1)
RNA editing (1)
RSV (4)
Schizophrenia (12)
Series A (41)
Series B (29)
Service/supplier (2)
Sickle cell disease (11)
Southern California (767)
Special edition (1)
Spinal muscular atrophy (36)
Sponsored (4)
Startups (984)
State (1)
Stomach cancer (2)
Supply chain (18)
Tariffs (7)
The Weekly (3)
United States (6336)
Vaccines (77)
Venture capitalists (7)
Weight loss (22)
Women's health (4)
Worklife (2)
Date
Today (41)
Last 7 days (231)
Last 30 days (737)
Last 365 days (8761)
2025 (2840)
2024 (9142)
2023 (9881)
2022 (11995)
2021 (12643)
2020 (9851)
2019 (6672)
2018 (5275)
2017 (6073)
2016 (5593)
2015 (6439)
2014 (4922)
2013 (4061)
2012 (4400)
2011 (4870)
2010 (4514)
Location
Africa (137)
Alabama (31)
Alaska (1)
Arizona (27)
Arkansas (2)
Asia (8491)
Australia (1997)
California (1940)
Canada (555)
China (112)
Colorado (30)
Connecticut (72)
Delaware (29)
Europe (18534)
Florida (180)
Georgia (27)
Idaho (10)
Illinois (127)
India (4)
Indiana (95)
Iowa (1)
Japan (35)
Kansas (11)
Kentucky (2)
Louisiana (1)
Maine (2)
Maryland (218)
Massachusetts (1414)
Michigan (68)
Minnesota (96)
Missouri (8)
Montana (8)
Nebraska (2)
Nevada (4)
New Hampshire (5)
New Jersey (419)
New Mexico (6)
New York (464)
North Carolina (273)
North Dakota (4)
Northern California (839)
Ohio (39)
Oklahoma (5)
Oregon (5)
Pennsylvania (389)
Puerto Rico (3)
Rhode Island (5)
South America (199)
South Carolina (1)
Southern California (767)
Tennessee (15)
Texas (221)
Utah (18)
Virginia (13)
Washington D.C. (8)
Washington State (325)
Wisconsin (6)
129,910 Results for "lixte biotechnology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
March 28, 2025
·
5 min read
Drug Development
LIXTE Biotechnology Holdings Provides Update on Recent Activities
LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s recent activities, including notable pre-clinical developments.
May 20, 2024
·
6 min read
Press Releases
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
March 11, 2025
·
4 min read
Press Releases
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
February 11, 2025
·
5 min read
Business
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
LIXTE Biotechnology Holdings, Inc. announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer.
June 3, 2024
·
5 min read
Press Releases
LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
February 14, 2025
·
5 min read
Business
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
LIXTE Biotechnology Holdings, Inc., a clinical stage pharmaceutical company, announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metastatic colon cancer.
June 14, 2024
·
5 min read
Business
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
LIXTE Biotechnology Holdings, Inc., a clinical stage pharmaceutical company, announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metastatic colon cancer.
June 14, 2024
·
4 min read
Biotech Beach
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
LIXTE Biotechnology Holdings, Inc. announced it is co-sponsoring an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s Dana Farber Cancer Institute on May 9 and 10, 2024 in Boston, Massachusetts.
May 8, 2024
·
4 min read
Business
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).
February 26, 2024
·
4 min read
1 of 12,991
Next
